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ABSTRACT
The Epstein–Barr virus (EBV) nuclear antigen 3 fam-
ily of protein is critical for the EBV-induced primary
B-cell growth transformation process. Using a yeast
two-hybrid screen we identified 22 novel cellular part-
ners of the EBNA3s. Most importantly, among the
newly identified partners, five are known to play di-
rect and important roles in transcriptional regulation.
Of these, the Myc-interacting zinc finger protein-1
(MIZ-1) is a transcription factor initially character-
ized as a binding partner of MYC. MIZ-1 activates
the transcription of a number of target genes includ-
ing the cell cycle inhibitor CDKN2B. Focusing on
the EBNA3A/MIZ-1 interaction we demonstrate that
binding occurs in EBV-infected cells expressing both
proteins at endogenous physiological levels and that
in the presence of EBNA3A, a significant fraction
of MIZ-1 translocates from the cytoplasm to the nu-
cleus. Moreover, we show that a trimeric complex
composed of a MIZ-1 recognition DNA element, MIZ-
1 and EBNA3A can be formed, and that interaction of
MIZ-1 with nucleophosmin (NPM), one of its coacti-
vator, is prevented by EBNA3A. Finally, we show that,
in the presence of EBNA3A, expression of the MIZ-1
target gene, CDKN2B, is downregulated and repres-
sive H3K27 marks are established on its promoter
region suggesting that EBNA3A directly counteracts
the growth inhibitory action of MIZ-1.
INTRODUCTION
Epstein–Barr virus (EBV) is a ubiquitous herpesvirus as-
sociated with several human cancers, both in immuno-
competent individuals (Burkitt’s lymphoma, Hodgkin’s dis-
ease (HD), rare T-cell and NK-cell lymphomas, undifferen-
tiated nasopharyngeal carcinoma (NPC), gastric carcino-
mas) and immuno-compromised individuals (lymphopro-
liferations and lymphomas, in particular in post-transplant
patients) (1). The primary infection is usually asymptomatic
when it occurs in childhood but later in life can result in the
infectious mononucleosis (IM). Following the primary in-
fection, the virus persists in a life-long latent state in the
memory B cells of infected individuals with intermittent vi-
ral production occurring in the oropharynx. In vitro, EBV
has the unique capacity to induce growth transformation
of resting primary human B-lymphocytes upon their infec-
tion, leading to the establishment of lymphoblastoid cell
lines (LCLs). In such cell lines, there is no virus production
but nine viral proteins––six nuclear antigens (EBNAs 1, 2,
3A, 3B, 3C and LP) and three membrane proteins (LMPs
1, 2A and 2B)––as well as several non-coding RNAs and
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miRNAs are expressed, that act in concert to induce and
maintain continuous proliferation (for a review see (2,3)).
The EBNAs 3A, 3B and 3C genes are arranged in tan-
dem in the EBV genome and are thought to originate from
a series of gene duplication events. Their structure is very
similar, with a short 5′-coding exon and a long 3′-coding
exon, and the resulting proteins share limited but signifi-
cant amino acid sequence homology, especially in their N-
terminal (NT) domains. Initial genetic studies using EBV
recombinants suggested that EBNA3A and EBNA3C (but
not EBNA3B) are absolutely required for the immortaliza-
tion of B lymphocytes in vitro (4). Moreover, LCLs that ex-
press conditional EBNA3A or EBNA3C mutant proteins,
cease to proliferate in the absence of functional EBNA3Aor
EBNA3C respectively (5,6). Recently, however, Hertle et al.
succeeded in establishing LCLs infectedwith a recombinant
EBV deficient for EBNA3A, although these cell lines ex-
hibit reduced proliferation rates and elevated levels of apop-
tosis (7).
The EBNA3s are functionally pleiotropic proteins that
have the properties of transcription factors but which are
also involved in the control of cell proliferation by di-
rectly interacting with proteins such as p53 (8) or Cyclin
A (9) and in the regulation of proteasome-dependent pro-
tein degradation by interacting with protein complexes such
as SCFSKP2 (10,11). EBNA3A and EBNA3C can cooper-
ate with H-RAS in the immortalization and transforma-
tion of rat embryonic fibroblasts (REFs) and relieve sup-
pression ofREF transformation by theCyclinD-dependent
kinase inhibitor (CDKI) p16INK4A (12–14). Through their
capacity to regulate transcription, the EBNA3s appear
to have important cell cycle-associated activities as well
as anti-apoptotic functions. In particular, EBNA3A and
EBNA3C cooperate to repress the expression of the pro-
apoptotic tumor-suppressor geneBCL2L11 (BIM) (15) and
the cyclin-dependent kinase inhibitor gene CDKN2A en-
coding p16INK4a (16,17).
The role of the EBNA3s as transcriptional regulators
was first characterized by the use of heterologous Gal4-
dependent reporter gene assays because they do not inter-
act with DNA directly. As full-length proteins, EBNA3A
and EBNA3C appear to act as transcriptional repressors,
but various domains of both proteins have been reported
to exhibit either an activating or repressive activity (18–22).
Transcriptional activation by the EBNA3 proteins could be
linked to their interaction with prothymosin alpha (PTMA)
and the histone acetyltransferase (HAT) p300 (23,24). Re-
pression by the EBNA3s has been shown to be mediated
by various co-repressor proteins or protein complexes in-
cludingC-terminal (CT)-binding protein 1 (CTBP1) (13,14)
and the histone deacetylases, HDAC1 and 2 (25,26). Fur-
thermore, it was recently shown that, by acting together,
EBNA3A and EBNA3C can trigger the recruitment of
polycomb repressive complex 2 (PRC2) core subunits to the
BIM promoter, leading to local trimethylation of histone
H3 on lysine 27 (H3K27me3) (27).
More recently, transcriptomic studies have revealed the
extent of the impact of the EBNA3s on cellular transcrip-
tion, with over 1000 host cell genes found to be regu-
lated by one or different combinations of the EBNA3s
in B cells (7,28–32). In addition, ChIP-sequencing (ChIP-
seq) analyses have identified up to 13 000 genomic sites
for the EBNA3s (32,33). However, cellular factors that re-
cruit the EBNA3s onto the chromatin have not as yet been
well defined except for the cellular DNA-binding factor
RBPJ (also called RBP-Jk or CBF1). RBPJ also binds
and targets both the EBV transcriptional activator EBNA2
and the Notch-IC effector of the Notch signaling pathway
to DNA. Acting alone, RBPJ is a transcriptional repres-
sor that recruits co-repressor complexes to its target pro-
moters. By interacting with RBPJ bound to specific DNA
sequences in the EBV C- and LMP1/LMP2 promoters,
EBNA2 appears to displace theRBPJ co-repressor complex
and thus activates the transcription of most EBV latency
genes––including the EBNA3s––expressed in the LCLs.
In transient reporter gene assays, the EBNA3s have been
shown to interfere with this RBPJ-dependent activation of
the viral C- and LMP1/LMP2Apromoters by EBNA2, and
are thus believed to be part of an auto-regulatory feedback
loop controlling EBNA2 as well as their own expression
(18,20,22,34,35).
In order to better understand the mechanisms involved
in the multiple functions of the EBNA3s, we used a large-
scale yeast two-hybrid (Y2H) screen to identify the princi-
pal interactions which each of the EBNA3 proteins makes
with the cellular proteome. From this screen, we have identi-
fied a number of relevant interactions between the EBNA3s
and cellular proteins, some of which allow the formula-
tion of new hypotheses that potentially fill the gaps in our
knowledge regarding the mechanisms of action of these
proteins. In particular, among the new interactors we have
identified, are several transcriptional regulators that bind
the core promoter elements of a number of genes known
to govern cell cycle progression. We focused our atten-
tion on one of them, ZBTB17, also known as MYC in-
teracting finger protein 1 (MIZ-1). MIZ-1 is a BR-C, ttk
and Bab (BTB)/Pox virus and Zing finger (POZ) domain-
containing transcription factor that binds to the transcrip-
tion initiator site (Inr) in the core promoters of target genes
(36,37) and depending on its binding partners, can func-
tion as an activator––by recruiting co-activators such as
p300 or the multifunctional cellular chaperone protein, nu-
cleophosmin (NPM, also known as B23, NO38 and Nu-
tramin) (38)––or as a repressor. One of the important part-
ners of MIZ-1 is MYC, which by binding MIZ-1, can re-
place the activating co-factors of MIZ-1. In the absence
of MYC, MIZ-1 activates expression of its target genes in
response to anti-mitogenic signals such as treatment with
growth inhibitory cytokine growth factor- (TGF) (37,39)
and exposure to DNA damage (40). Thus, whereas MIZ-
1 alone has growth arrest activity by activating the expres-
sion of target genes such as CDKN1A (encoding p21WAF1),
CDKN2B (encoding p15INK4b) and CDKN1C (encoding
p57KIP2), the MAX–MYC–MIZ-1 complex represses their
expression (for a review see (41)). Other transcriptional reg-
ulators such as BCL-6 (42,43), GFI-1 (44) and HCF-1 (45)
have been shown to interact with MIZ-1 and repress the
transcription in a similar way to MYC. Furthermore, the
p14ARF tumor suppressor protein has been shown to both
disrupt the interaction between MIZ-1 and NPM, and in-
duce MIZ-1 sumoylation (46).
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We show here that all three EBNA3 proteins interact with
MIZ-1. Focusing on EBNA3A we show that its expres-
sion in LCLs is responsible for transcriptional repression
of the MIZ-1-specific target gene CDKN2B. Furthermore,
we show that EBNA3A expression induces delocalization
of MIZ-1 from the cytoplasm to the nucleus and correlates
with an increase in the H3K27me3 mark at the CDKN2B
promoter. Finally, we provide evidence that EBNA3A also
represses MIZ-1 target gene expression by interfering with
the recruitment of its coactivator, NPM.
MATERIALS AND METHODS
Plasmids
Open Reading frames (ORFs) for full-length EBNA3A,
EBNA3B, EBNA3C, EBNA3A-Nter (aa 1 to 310),
EBNA3B-Nter (aa 1 to 325), EBNA3C-Nter (aa 1 to
320), EBNA3A-Cter (aa 274 to 944), EBNA3B-Cter (aa
279 to 938) and EBNA3C-Cter (aa 284 to 992) were
cloned using the Gateway recombinational cloning system
(47) and deposited in a viral ORF repository, viralOR-
Feome (48). Each ORF was polymerase chain reaction
(PCR)-amplified (KOD polymerase, Novagen) from
pSG5-EBNA3A/3B/3C (20) using reverse and forward
primers containing the attB1 and attB2 recombination sites
respectively, then cloned into pDONR207 (BP Clonase,
Invitrogen). The ORFs were subsequently transferred (LR
Clonase, Invitrogen) into the bait vector, pGBKT7, to
be expressed as GAL4-DB fusions in yeast. Expression
plasmids for EBNA3A, 3C, 3B tagged with the Flag or
Myc epitopes were obtained by recombinational cloning
from the pDONR207 vectors into expression vectors pCI-
neo-3xFlag-gw and pDEST-myc (kindly provided by Dr
Y. Jacob) respectively. Expression plasmids for the cellular
proteins identified in the Y2H screen were obtained either
by recombinational cloning using a human ORFeome
library (cloned into pDONR223) into expression vector
pDEST-myc or by RT-PCR amplification from HeLa cells
mRNAor were kindly given byDr J. Lukas (FBXO18) (49),
Dr M. Eilers (MIZ-1) (37), Dr K. Tang (CENPJ) (50), Dr
A. M. Naar (MED25) (51), Dr E. Krueger (PSMA7) (52).
MIZ-1 and EBNA3A deletion mutants were generated by
cloning the corresponding PCR-amplified fragments into
pDONR207, which were transferred into pCI-neo-3xFlag-
gw or pDEST-myc. EBNA3A deletion mutant 141–238
and EBNA3A-CtBPmut, in which the two amino acid
motifs, ALDLS (aa 857–861) and VLDLS (aa 886–890)
are substituted by ALDAA and VLDAA respectively,
were generated by site-directed mutagenesis (QuickChange
Site-Directed Mutagenesis kit, Stratagene). The CDKN2B
(−113- +160) Luc reporter construct was a kind gift from
Dr Eilers. The CMV-Renilla Luciferase plasmid used as
an internal control in the transfection has been described
previously (53).
Yeast two-hybrid screens
The screens were made using matings between the
AH109 and Y187 yeast strains (Clontech) (54,55). Bait
vectors, pGBKT7-EBNA3A/3A-Nter/3A-Cter, pGBKT7-
EBNA3B/3B-Nter/3B-Cter, pGBKT7-EBNA3C/3C-
Nter/3C-Cter were transformed into AH109 (bait strain).
A human LCL AD-cDNA library (56) and a human
spleen normalized AD-cDNA library (Invitrogen) were
transformed into Y187 (prey strain). Single bait strains
were mated with prey strain, then diploids were plated
on SD-W-L-H + 5 mM 3-AT medium. Positive clones
were maintained on this selective medium for 15-days
to eliminate any contaminating AD-cDNA plasmid
(57). AD-cDNAs were amplified by colony PCR and
inserts were sequenced and identified by automatic Basic
Local Alignment search Tool (BLAST) as described
previously (58).
Cell culture and transfections
HeLa cells and HEK293T cells were grown at 37◦C in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum (FBS) and penicillin-streptomycin.
LCLs generated from B cells derived from two different
donors––donor 1 (D1) and donor 2 (D2)––and infected
with either wild-type (wt) recombinant EBV (D1wt, D2wt)
or EBNA3A knock-out virus (D1E3AmtA, D2E3AmtB1,
D2E3AmtB2, D2E3AmtB3) have been described previ-
ously (7) as well as the E3A-LCLdoxE3A LCL (31) and
were maintained in Advanced RPMI 1640 medium supple-
mentedwith 10%FBS and penicillin-streptomycin. Plasmid
transfection was performed using either the calcium phos-
phate precipitate method or the PEI transfection reagent
(Polysciences). Treatment of LCLs with theMYC inhibitor,
10058-F4 (Calbiochem) was performed at a concentration
of 64Mfor 24 h. Treatmentwith cisplatin (Sigma-Aldrich)
was performed at 33 M concentration.
Flow cytometry analysis
For quantification of NGFR-expressing cells, cells were
stained with APC-coupled mouse anti-human CD71
(NGFR) antibody (BioLegend). For cell cycle analysis cells
were stained with Propidium Iodide (Abcam) using stan-
dard protocols. Fluorescence of cells was detected and ana-
lyzed using a FACSCalibur system and CellQuest Pro soft-
ware (BD Biosciences).
Co-immunoprecipitation assays and western blots
Transfected HEK293T or HeLa cells were harvested from
100 mm dishes 48 h post-transfection and lysed in IP
buffer (50 mM Tris-HCl pH 7.5, 150–300 mMNaCl, 1mM
Dithiotreitol (DTT) and 0.5% Nonidet P-40) plus protease
inhibitors (Roche Molecular Biochemicals). For immuno-
precipitation of the transiently expressed Flag-tagged pro-
teins, cell extracts were incubated with 30 l anti-Flag
M2 affinity gel (Sigma) for 4 h at 4◦C and the immunop-
urified proteins were analyzed by western blotting. An-
tibodies used for other immunoprecipitations or western
blotting analysis were anti-Flag rabbit polyclonal anti-
body (Sigma), anti-Myc (9E10) mAb, anti-human MIZ-1
goat polyclonal antibody (R & D Systems), anti-EBNA3A
sheep polyclonal antibody (Exalpha biologicals Inc), anti-
Nucleophosmin mAb (Invitrogen) and anti--tubulin mAb
(B-5–1–2, Sigma). The appropriate anti-mouse (GEHealth-
care), anti-rabbit (GE Healthcare), anti-goat (Santa Cruz
Nucleic Acids Research, 2014, Vol. 42, No. 15 9703
Biotechnology, Inc) or anti-sheep (Abcam) horseradish per-
oxidase (HRP)-conjugated antibodies were used as sec-
ondary antibodies. Myc-tagged proteins were also revealed
using Myc (9E10) HRP-conjugated antibody (Santa Cruz
Biotechnology, Inc). Western blots were revealed using En-
hanced Chemiluminescence (ECL) (Pierce).
In vitro GST Pull-down assays
Glutathione S-Transferase (GST) and GST-fusion proteins
were purified from Escherichia coli BL21 (DE3) codon
plus strain extracts, with glutathione-Sepharose 4B beads
(GE Healthcare). Beads carrying the GST or the GST-
fusion proteins were equilibrated in the following bind-
ing buffer (10 mM Tris-HCL pH 8, 250 mM NaCl, 0.1%
NP40 and 2 mg/ml bovine serum albumin (BSA)) in
the presence of protease inhibitors (complete EDTA-free
cocktail from Roche Molecular Biochemicals) and incu-
bated with radiolabeled proteins synthesized in vitro in
the presence of [35S]-methionine using the TnT Coupled
Transcription/Translation system (Promega), in binding
buffer for 4 h at 4◦C. Beads were washed 5× in bind-
ing buffer without BSA and bound proteins were fraction-
ated by sodium dodecylsulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and revealed by autoradiography.
Oligo pull-down assays
Cells were lysed by sonication in Hepes, KCl, MgCl2, Glyc-
erol (HKMG) buffer (10 mM HEPES, pH 7.9, 100 mM
KCl, 5 mMMgCl2, 10% glycerol, 1 mMDTT, 0.5% NP40)
containing protease and phosphatase inhibitors. Cellular
debris was removed by centrifugation. Then, 1 mg of to-
tal lysate was precleared with 40 l of streptavidin-agarose
beads (Thermo Scientific) for 1 h at 4◦C, with rotation,
and incubated with 2 g of biotinylated double-stranded
oligonucleotide (Table S1, Supplementary Data) and 20
g of poly(dI-dC) for 16 h at 4◦C, with rotation. Biotin-
oligonucleotide-protein complexes were collected with 60
l of streptavidin-agarose beads for 1 h at 4◦C with rota-
tion, washed twice with HKMG buffer, separated on SDS-
PAGE, and detected by western blotting.
RNA analysis
RNAs were prepared using the Nucleospin RNA kit
(Macherey-Nagel) and reverse transcribed using the
qScriptTM cDNA SuperMix (Quanti Biosciences). Stan-
dard PCRs were performed using the GoTaq R©DNA
polymerase (Promega) and the PCR-amplified fragments
were analyzed on 2% agarose gels. We used ß-actin mRNA
as internal control. Amplification of a single 690-bp DNA
fragment corresponding to the ß-actin mature mRNA
showed that no DNA contamination was present in our
RNA preparations. qPCR was performed using FastStart
Universal SYBR Green Master (Rox) (Roche Molecular
Biochemicals) on an Applied Biosystems 7000 thermocy-
cler. Cycling conditions were 5 min at 95◦C and 45 cycles
of 15 s at 95◦C, 30 s at 60◦C on a 96-well thermoblock.
This program was followed by melting curve analysis in
order to verify the specificity of the PCR product. PCR
results were normalized with the parallel amplification of
GAPDH mRNA. The various set of primers used in the
study are listed in Table S1 of Supplementary Data.
Immunofluorescence assays
For indirect immunofluorescence experiments, anti-Flag
polyclonal antibody (Sigma) and anti-Myc 9E10 mAb were
used as primary antibodies. Alexa Fluor 488 goat anti-
rabbit antibody (Invitrogen) and Fluorolink Cy3-labeled
goat anti-mouse IgG (H + L) (GE Healthcare) were used
as secondary antibodies. Cell nuclei were stained by in-
cubation with 0.5 g/ml Hoescht 33342 (Sigma). Slides
were examined using confocal microscopy (Zeiss LSM 710)
with ZEN software for the photos and standardmicroscopy
(Zeiss Axiovert 135) with Image J software for counting the
cells.
Luciferase Assays
Renilla or Firefly luciferase activities from transfected
cells were measured in a VeritasTM Luminometer (Turner
Biosystems) using the Renilla or Firefly Luciferase As-
say system (Promega Madison Co). Luciferase activity was
measured for identical amounts of total protein as evaluated
by Bradford assay.
Chromatin immunoprecipitations
Chromatin immunoprecipitations (ChIPs) were performed
as described in the Upstate protocol. Briefly, lymphoblas-
toid cells were cross-linked with 1% formaldehyde at RT
for 10 min. Crosslinked chromatin was sonicated using the
Bioruptor R© from Diagenode in order to obtain sheared
chromatin, yielding fragments of 150 to 500 bp. Sheared
chromatin generated from the equivalent of 1–2 × 106 cells
was used per ChIP. Antibodies used to immunoprecipitate
methylated histones were rabbit polyclonal anti-trimethyl-
Histone H3 (Lys27) antibody (07–449 Millipore) and anti-
dimethyl-Histone H3 (Lys4) mAB (clone AW30; 04–790
Millipore). Rabbit IgG (PP64 Millipore) or mouse IgG
(PP54 Millipore) were used respectively as negative con-
trol antibodies. Precipitated DNAwas assayed by quantita-
tive PCR as described in the RNA analysis section and the
amount of immunoprecipitated chromatin was expressed
fromduplicate assays as percentage of input chromatin. The
different primers used are listed in Table S1 of Supplemen-
tary Data.
RESULTS
Identification of novel cellular interacting partners for
EBNA3A, EBNA3B and EBNA3C by yeast two-hybrid
screening
We used the Y2H system to identify cellular proteins that
interact with the EBNA3 family of proteins. Six constructs
encoding either full-length, NT or CT regions of EBNA3A,
EBNA3B and EBNA3C were used to probe both a human
LCL cDNA library and a human spleen cDNA library. Five
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hundred ninety-seven cDNA clones were initially charac-
terized following PCR amplification of the cDNAs and se-
quencing. From these, a majority were identified as cor-
responding to RBP-J cDNAs. The characterization of the
rest of the clones allowed us to identify 35 different puta-
tive interactors. We then validated the interactions between
the putative novel cellular partners and each of the EBNA3
proteins via co-immunoprecipitation assays in HEK293T
cells, following transfection of expression plasmids encod-
ing full-length proteins. Twenty-seven cellular proteins were
thus identified as true cellular EBNA3-interacting proteins
(Table 1 and Supplementary Figure S1). Most appeared
to interact with all three EBNA3 proteins, even though
they were often identified only with one EBNA3 in the
Y2H screen. However, it is to be noted that in several cases
we observed important differences in the efficiency of co-
immunoprecipitation of a specific partner depending on the
EBNA3 used.
From our list of cellular interactors, six (namely RBPJ
(20,59–61), CTBP1 (13,14,17), ZYX (62), CENPJ and
EIF3F (63)) had been previously described as direct inter-
actors of at least one of the EBNA3 proteins. Interestingly,
our systematic validation, by co-immunoprecipitation in a
mammalian expression system, of interaction with the three
EBNA3s allowed us to complete the description of these
previously known interactions. ZYXIN was previously
identified in a Y2H screen using EBNA3B as a bait (62).
We validated this interaction by co-immunoprecipitation
with both EBNA3B and EBNA3A (Supplementary Fig-
ure S1). Both CENPJ and EIF3F were previously identi-
fied in a Y2H screen using EBNA3C as a bait (63). We vali-
dated these interactions with both EBNA3C and EBNA3A
for CENPJ and with all three EBNA3s for EIF3F (Supple-
mentary Figure S1). The interaction of both EBNA3A and
EBNA3Cwith theCtBP1 co-activator has already beenwell
characterized (13,14,17). We also found an interaction with
CtBP2, a protein highly related to CtBP1 (80% homology)
(64) (Supplementary Figure S1). Finally, EBNA3Awas pre-
viously found, by co-immunoprecipitation, to form a com-
plex with HSP40 (DNAJB1) in LCLs (28). The fact that we
identified this cellular partner by Y2H suggests a direct in-
teraction between the two proteins. Moreover, we show that
EBNA3B and EBNA3C can also be found in a complex
with DNAJB1 (Supplementary Figure S1). We also identi-
fied several interactors that are part of protein complexes
previously shown to be targeted by the EBNA3s. This is
the case for STIP1 (also called HOP for HSC70/HSP90-
organizing protein) which facilitates the association of the
HSP70/HSP90 chaperone complex (65): EBNA3A has pre-
viously been shown to interact withHSP70 andHSP90 (28).
This is also the case for FBXO18 (F-box protein, helicase,
18) which forms a SCF (SKP1/Cullin/F-box) complex with
human CUL1 and ROC1 (66): EBNA3C has previously
been shown to interact with the SCFSKP2 complex (9,10).
EBNA3C (and EBNA3A) could thus potentially interact
with several different SCF complexes.
Most importantly, we identified several novel interactors
which have functions linked to transcriptional regulation,
either directly, as DNA-binding transcriptional regulators
(ZBTB17, NFYC andMEOX1) or co-activators/repressors
(CtBP2,MED25 andMCRS1), or indirectly as components
of the ubiquitin/proteasome pathway (FBXO18, SUMO2,
COPS5). Of these novel interactors we became particularly
interested in ZBTB17, which is more frequently referred to
asMIZ-1 (forMYC-interacting zinc-finger protein 1).MIZ-
1 is a POZ-ZF factor that binds to transcription Inr in the
core promoter of target genes of important regulators of the
cell cycle i.e. CDKN1A, CDKN2B and CDKN1C (36,37).
We thus decided to further characterize the interactions be-
tween the EBNA3 proteins and MIZ-1.
All three EBNA3 proteins interact with the cellular protein
MIZ-1 both in cellulo and in vitro
Since all MIZ-1 cDNAs isolated from the screen contain
only sequences coding for the CT region of the protein, each
possessing a variable number of internal zinc finger repeats
(nine for the longest) (Figure 1A), we first checked if the
EBNA3s interact with full-length MIZ-1 (FL-MIZ-1). For
this, we performed a co-immunoprecipitation assay using
HeLa cells transfected with expression vectors for FL-MIZ-
1 tagged with a Myc epitope, and each one of the EBNA3s
tagged with a Flag epitope. As can be seen in Figure 1B,
FL-MIZ-1 was specifically co-immunoprecipitated with all
three EBNA3s.
To confirm thatMIZ-1 interacts directly with the EBNA3
proteins we performed a GST-Pulldown assay using GST-
MIZ-1 383–803 (Figure 1A) produced in bacteria and 35S-
EBNA3 proteins in vitro-translated in reticulocyte lysates.
As shown in Figure 1C, EBNA-3A, -3B and -3C are all ef-
ficiently retained on GST-MIZ-1 383–803 but not on GST
alone, which strongly suggests a direct interaction between
MIZ-1 and each of the EBNA3s.
We next decided to investigate more specifically the phys-
ical and functional interactions between EBNA3A and
MIZ-1. By reciprocal co-immunoprecipitation assays (Fig-
ure 1D) we demonstrated that endogenous MIZ-1 and
EBNA3A can form a complex under physiological condi-
tions in a relevant cell model––i.e. lymphoblastoid cells im-
mortalized by EBV.
The N-terminal domain of EBNA3A interacts with two dif-
ferent domains within MIZ-1
In order to precisely map the MIZ-1 domain(s) interacting
with EBNA3A,we generated a series ofMIZ-1 deletionmu-
tants (Figure 2A) and performed co-immunoprecipitation
assays. We first tested two complementary MIZ-1 mutants
consisting of either the NT or the CT half of the protein.
As can be seen in Figure 2B, both FL-MIZ-1 andMIZ-1CT
interact with EBNA3A, whereas MIZ-1NT does not. This
corroborates our finding that all MIZ-1 clones isolated in
the Y2H screen contained the CT half of the protein albeit
with a variable number of zinc finger motifs. We then tested
a series of CT deletion mutants. As shown in Figure 2C,
the mutants 1, 2 and 3 were all very inefficiently co-
immunoprecipitated (lanes 3, 4, 5). By contrast, deletion of
the zinc finger motif within the CT domain (mutant Z13)
had no effect (lane 6), neither did deletion of the domain
between aa 638 and 716 previously shown to be required
for the interaction with MYC (36) (Figure 2D, lane 9). In-
terestingly, we also found an interaction between the POZ
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Table 1. List of cellular proteins interacting with EBNA-3A/-3B/-3C identified in the Y2H screens and validated in cellulo by co-immunoprecipitations
in HEK293T cells
GeneID Hits Gene symbol Full name Y2H CoIP
3516 475 RBPJ* Recombination signal binding protein for immunoglobulin
kappa J
A B C ND
1487 25 CTBP1* C-terminal binding protein 1 A C CCt ND
7791 11 ZYX* Zyxin B BCt A B
55835 6 CENPJ* Centromere protein J B BCt C A C
3337 6 DNAJB1* DnaJ (Hsp40) homolog, subfamily B, member 1 A A B C
7709 6 ZBTB17 Zinc finger and BTB domain containing 17 B CCt A B C
MIZ-1# Myc-Interacting Zn Finger Protein 1#
84893 5 FBXO18 F-box protein, helicase, 18 C CNt A C
151887 4 CCDC80 Coiled-coil domain containing 80 C CCt A B C
10987 4 COPS5 COP9 constitutive photomorphogenic homolog, subunit 5 ANt CNt A B C
23557 3 SNAPIN SNAP-associated protein ANt CNt A B C
6613 3 SUMO2 SMT3 suppressor of mif two 3 homolog 2 CCt A B C
1488 2 CTBP2 C-terminal binding protein 2 A A B C
4802 2 NFYC Nuclear transcription factor Y, gamma A A B
5536 2 PPP5C Protein phosphatase 5, catalytic subunit A A B C
409 1 ARRB2 Arrestin, beta 2 A A B C
8665 1 EIF3F* Eukaryotic translation initiation factor 3 subunit F C A B C
3190 1 HNRNPK Heterogeneous nuclear ribonucleoprotein K CNt C
3843 1 IPO5 Importin 5 ANt A B C
10445 1 MCRS1 Microspherule protein 1 CCt A B C
81857 1 MED25 Mediator complex subunit 25 A A B C
4222 1 MEOX1 Mesenchyme homeobox 1 A A B C
9260 1 PDLIM7 PDZ and LIM domain 7 CCt A B C
5688 1 PSMA7 Proteasome subunit, alpha, type 7 CNt A B
6136 1 RPL12 Ribosomal protein L12 C A B C
6138 1 RPL15 Ribosomal protein L15 A A B C
10963 1 STIP1 Stress induced phosphoprotein 1 A A B C
79090 1 TRAPPC6A Trafficking protein particle complex 6A A A B C
Each human gene is identified by its National Center for Biotechnology Information (NCBI) gene ID (first column), gene symbol (third column) and full
name (fourth column). The number of hits indicated (second column) is given without discrimination of the bait protein. Column 5 indicates with which
bait protein(s) the cellular partner has been identified in Y2H. Column 6 indicates which of the EBNA-3A/-3B/-3C have been validated with the cellular
partner by co-immunoprecipitation in cellulo. A: EBNA3A, B: EBNA3B, C: EBNA3C, ANt : EBNA3A (1–310), BCt : EBNA3B (1–325), CNt : EBNA3C
(1–320), CCt : EBNA3C (279–938). ND: Not Done. * Indicates cellular partners for which an interaction with at least one of the EBNA3 was previously
described. # Alternative name.
domain of MIZ-1 and EBNA3A (Figure 2D, lane 12). This
interaction appears to be as efficient as the interaction ob-
served with FL-MIZ-1. This was unexpected since the mu-
tants 1, 2, 3 and NT, that all contain the POZ domain
do not interact efficiently with EBNA3A, suggesting that
the capacity of the POZ domain to interact with EBNA3A
is strongly perturbed in these deletion mutants. In conclu-
sion, EBNA3A binds independently to both the NT POZ
domain (aa 1–104) and the extreme CT (aa 739–803) of
MIZ-1.
We then delimited the interaction domain of EBNA3A
with MIZ-1. Because all three EBNA3s are able to inter-
act with MIZ-1, we suspected the interaction domain to
be localized within the homology domain of the EBNA3s
(Figure 3A). We thus made use of an EBNA3A mutant
with aa 141–238 deleted to test this hypothesis and in-
deed, co-immunoprecipitation of this deletion mutant with
MIZ-1was drastically reduced (Figure 3B). The importance
of this domain for the interaction with both the MIZ-1
POZ domain and the MIZ-1 383–803 CT domain was then
confirmed by GST-pulldown experiments (Supplementary
Figure S2). Moreover, by using a series of NT and CT
EBNA3A deletion mutants, we found that EBNA3A con-
tacts the POZ domain of MIZ-1 via a minimum domain
comprising aa 125–172 and that it also interacts with the
CT of MIZ-1 via several regions––a major region is located
in the first 224 NT amino acids of the protein and another
in the CT half of the protein (Supplementary Figure S2).
EBNA3A expression induces nuclear localization of MIZ-1
MIZ-1 was previously described to be present mostly in the
cytoplasm of HeLa cells with only a small proportion of the
protein being localized in the nucleus. However, in the pres-
ence of overexpressed MYC, most cells show an exclusive
nuclear localization pattern ofMIZ-1 (36). Since EBNA3A,
likeMYC, is a nuclear protein, we asked whether the expres-
sion of EBNA3A would also induce nuclear localization of
MIZ-1. We thus co-transfected HeLa cells with an expres-
sion vector for MIZ-1 tagged with a Flag-epitope, together
or not with an expression vector for EBNA3A tagged with
a Myc-epitope. Immunofluorescence staining of the cells
demonstrates that, as expected, MIZ-1 expressed alone is
either fully cytoplasmic or nucleo-cytoplasmic in amajority
of the cells (Figure 4A and C). By contrast, in the presence
of EBNA3A, MIZ-1 is exclusively nuclear in most of the
cells (Figure 4B and C). From these experiments, we con-
clude that co-expression of the two proteins results in their
functional interaction and consequent migration of MIZ-1
from the cytoplasm to the nucleus.
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Figure 1. The EBNA3 proteins interact with the cellular protein MIZ-
1. (A) Schematic representation of MIZ-1. The black box corresponds
to the POZ domain of the protein and the dark gray boxes to zinc fin-
ger motifs. MIZ-1 380–803 corresponds to the protein expressed from the
longest cDNA isolated in the Y2H screen. (B) Expression plasmids for
Flag-EBNA3A (F.E3A), Flag-EBNA3B (F.E3B), Flag-EBNA3C (F.E3C)
andMIZ-1 were transfected into HeLa cells as indicated. Cellular extracts
were immunoprecipitated with an M2 anti-Flag mAb affinity gel and the
immunoprecipitated complexes were analyzed bywestern blotting using an
anti-Flag polyclonal antibody to detect the EBNA3 proteins (top panel)
or an anti-Miz polyclonal antibody (bottom panel). Input corresponds
to 8% of the cell extracts used for immunoprecipitation. (C) 35S-labeled
EBNA3A, EBNA3B or EBNA3C were incubated with purified GST or
GST-MIZ-1 383–803 bound to glutathione sepharose beads. The bound
proteins were analyzed by SDS-PAGE and visualized by autoradiogra-
phy. In lane 1, the equivalent of one-twelfth of the EBNA3A, EBNA3B
or EBNA3C-expressing rabbit reticulocyte lysates used in each assay was
loaded onto the gel. (D) EBNA3A or MIZ-1 were immunoprecipitated
(IP) from a lymphoblastoid cell line protein extract using anti-EBNA3A
or anti-MIZ-1-specific polyclonal antibodies as indicated or with an anti-
Flag antibody as control. Immuno and co-immunoprecipitated EBNA3A
andMIZ-1 proteins were analyzed by western blotting. Input corresponds
to 25% of the cell extract used for immunoprecipitation.
EBNA3A downregulates the expression ofMIZ-1 target gene
CDKN2B in LCLs
Because MIZ-1 is implicated in the transcriptional regula-
tion of the cyclin-dependent kinase inhibitor geneCDKN2B
(encoding p15INK4B), we asked whether EBNA3A canmod-
ulate the expression of this gene. For this, we compared the
level of transcript expressed in a B-LCL established with wt
EBV (LCLwt) to that expressed in a LCL (LCL3A) infected
with an EBV mutant deficient for EBNA3A (E3AmtB mu-
tant) (7). We first verified that the level of MIZ-1 protein
was not affected by the presence or absence of EBNA3A
in the LCLs (Supplementary Figure S3A). We then ana-
lyzed the levels of the CDKN2B transcript by standard and
quantitative RT-PCR (Figure 5A and B). Interestingly, the
level of the CDKN2B transcripts was drastically reduced
in the presence of EBNA3A. We confirmed these observa-
tions in several LCLs immortalized independently with the
E3AmtB mutant as well as LCLs obtained using a different
donor and immortalized with a different type of EBNA3A-
deficient mutant (mutant E3AmtA (7)). In all cases, we
observed a similar decrease in CDKN2B RNA levels in
the LCLs expressing EBNA3A compared to their counter-
part infected with EBNA3A-deficient viruses (Supplemen-
tary Figure S3B). Finally, we analyzed the repression kinet-
ics of CDKN2B. For this we made use of a LCL that ex-
presses EBNA3A in a doxycycline (Dox) dependent man-
ner (E3A-LCLdoxE3A) (31). As can be seen in Figure 5C,
the transcript levels of CDKN2B fell rapidly––within 24
h––upon EBNA3A induction. Interestingly, we also ob-
served a downregulation in the expression of CDKN1C
andCEBPD––two genes that have previously been reported
to be directly regulated by Miz-1 (41,67,68)––in the pres-
ence of EBNA3A (Supplementary Fig S4). In the case of
CDKN1A––also a well documented target gene of Miz-
1––we only observed a marginal, but reproducible, increase
(Supplementary Figure S4). Moreover, in a recent paper
Yenamandra et al. (69), using these same LCLs, found a 8-
fold decrease in the level ofCDKN1A transcripts in the pres-
ence of EBNA3A, which supports a role for EBNA3A in
CDKN1A regulation. From these results we conclude that
EBNA3A can repress transcription of MIZ-1 target genes.
However, the above experiments were made using nor-
mal proliferating cells in which the level of CDKN2B tran-
script is expected to be low. By contrast, CDKN2B expres-
sion is known to be activated at the transcriptional level
in a MIZ-1-dependent manner in response to UV irradi-
ation, DNA damage or treatment with TGF (39,70,71).
In order to test the impact of EBNA3A in conditions
where CDKN2B expression is activated, we used cisplatin
as a DNA-damage inducing agent. Cell cycle analysis re-
vealed that treatment with cisplatin of either LCLwt or
LCL3A results in cell growth arrest and apoptosis as pre-
viously reported (72,73), but the response to the cisplatin
treatment is clearly delayed in the case of LCLwt com-
pared to LCL3A (Figure 6B). In parallel, quantification
by RTqPCR (Figure 6A) of CDKN2B transcript levels in
the case of LCL3A over a 12 h time course period, shows
a very rapid increase––within 4 h––in CDKN2B transcript
levels. The maximum––a 10-fold increase––is reached after
12 h, beyond which the state of the cells did not allow fur-
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Figure 2. EBNA3A interacts with two distinct domains of Miz1. (A) Schematic representation of MIZ-1 and MIZ-1 deletion mutants. (B, C and D)
Expression plasmids for Myc-EBNA3A and Flag-MIZ-1 or Flag-MIZ-1 deletion mutants were transfected into HeLa cells as indicated. Cellular extracts
were immunoprecipitated with an M2 anti-Flag mAb affinity gel and the immunoprecipitated complexes were analyzed by western blotting using an anti-
Flag polyclonal Flag antibody to detect MIZ-1 and the MIZ-1 deletion mutants or an anti-Myc 9E10 mAb to detect Myc-EBNA3A. Inputs correspond
to 8% of the cell extract used for immunoprecipitation.
ther RNA quantification. In the case of LCLwt, the levels
of theCDKN2B transcript are also induced following treat-
ment with cisplatin––with a pattern similar to that observed
in LCL3A––but the levels remain very low, staying in the
range observed in LCL3A before treatment with cisplatin.
Taken together, these results indicate that EBNA3A ef-
ficiently represses CDKN2B expression and that in condi-
tions where this expression is induced by stimuli such as
DNA-damage, this repression allows the retention of low
levels of CDKN2B transcript compatible, at least to a cer-
tain extent, with cell survival.
EBNA3A represses MIZ-1-mediated activation of a minimal
CDKN2B gene promoter and interacts with a specificMIZ-1
target DNA probe containing an Inr sequence
We next wanted to determine whether the repression effect
of EBNA3A on CDKN2B expression was directly linked to
MIZ-1 regulation of the CDKN2B promoter. To this end,
we used a reporter construct in which the Firefly luciferase
coding sequence was placed under the control of a mini-
malCDKN2B promoter (−113/+160). This contains an Ini-
tiator element (Inr) previously shown to recruit MIZ-1 to
the promoter by direct binding of the protein to this se-
quence (37) (Figure 7A). As shown in Figure 7B, the re-
porter construct was activated by MIZ-1 in HeLa cells and
this activation was efficiently repressed by EBNA3A but
not by EBNA3A 141–238, a deletion mutant whose in-
teraction with MIZ-1 is drastically reduced. These results
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Figure 3. MIZ-1 interacts preferentially with the EBNA3 homology
domain of EBNA3A. (A) Schematic representation of EBNA3A and
EBNA3A deletion mutant. (B) Expression plasmids for Flag-MIZ-1 and
Myc-EBNA3A or Myc-EBNA3A 141–238 were transfected into HeLa
cells as indicated. Cellular extracts were immunoprecipitated with an M2
anti-Flag mAb affinity gel and the immunoprecipitated complexes were
analyzed by western blotting using an anti-Flag polyclonal antibody to de-
tect MIZ-1 or an anti-Myc 9E10 mAb to detect Myc-EBNA3A and Myc-
EBNA3A 141–238. Input corresponds to 8% of the cell extract used for
immunoprecipitation.
indicate that EBNA3A specifically repressesCDKN2B tran-
scriptional activation by MIZ-1.
We then used an oligonucleotide precipitation assay to
address whether MIZ-1 can recruit EBNA3A to the pro-
moter of CDKN2B. For this, whole cell extracts of an
LCLwt, endogenously expressing MIZ-1 and EBNA3A,
were incubated with biotinylated double-stranded oligonu-
cleotide containing the Inr sequence of the human
CDKN2B promoter (or a control oligonucleotide with four
bases mutated) (Supplementary Table S1). Bound pro-
teins were precipitated using streptavidin-coated beads. As
shown in Figure 7B, both MIZ-1 and EBNA3A were pre-
cipitated with the Inr oligonucleotide, but not with the mu-
tated oligonucleotide, strongly suggesting that MIZ-1 re-
cruits EBNA3A to its specific binding site on the DNA.
Repression of CDKN2B expression by EBNA3A is associ-
ated with an increase in H3K27me3 at the CDKN2B pro-
moter
EBNA3 proteins have previously been found to trigger the
recruitment of polycomb repressive complex 2 (PRC2) core
subunits and the trimethylation of H3K27 around both the
BCL2L11 promoter (27) and the CDKN2A locus encod-
ing p16INK4a and p14ARF (17,16). We thus investigated the
variation in H3K27 and H3K4 methylation levels at the
CDKN2B promoter, depending on the presence or absence
of EBNA3A. For this, ChIP, coupledwith quantitative PCR
(qPCR) assays directed across the CDKN2B locus (Fig-
ure 8A), were performed using EBVwt and EBV3A LCLs.
As can be seen in Figure 8B, the presence of EBNA3A
correlates with a net increase in the repressive H3K27me3
mark, specifically centered on the site of the Inr motif. Con-
comitantly, as shown in Figure 8C, the H3K4 methyla-
tion was only marginally changed, which is reminiscent of
what has also been observed in the case of the BCL2L11
and CDKN2A loci (27,17,16). From these experiments we
conclude that the repression mechanism of CDKN2B ex-
pression by EBNA3A is due, at least partially, to epige-
netic modifications, in particular the increase in H3K27
tri-methylation similar to what has been observed for the
BCL2L11 and CDKN2A promoter regions.
EBNA3A represses MIZ-1-mediated activation of the
CDKN2B promoter in a CTBP-independent manner
Although we found a good correlation between the pres-
ence of EBNA3A and epigenetic modifications, these mod-
ifications do not likely account for the very rapid tran-
scription shut-down of CDKN2B following Dox-induced
expression of EBNA3A. Since EBNA3A has previously
been shown to repress transcription by recruiting the co-
repressor CTBP1 (13), we first asked whether the inter-
action of EBNA3A with CTBP1 was required for the re-
pression ofMIZ-1-dependent transcriptional activation. As
EBNA3A has been shown to interact with CTBP1 via two
motifs, ALDLS and VLDLS, located in the CT part of
EBNA3A, we generated an EBNA3A mutant with these
two motifs mutated (EBNA3A-CTBPmut) (13). We then
compared the capacity of this mutant to inhibit MIZ-1-
dependent transcriptional activation of our reporter con-
struct with that of wild-type EBNA3A. As can be seen
Figure 9A, EBNA3A-CTBPmut repressesMIZ-1 transcrip-
tional activation as efficiently as EBNA3A, indicating that
CTBP binding to EBNA3A is not required for its downreg-
ulation of the CDKN2B promoter.
EBNA3A downregulation ofCDKN2B expression is indepen-
dent of MYC
Regulation by MIZ-1 of Inr-containing promoters involves
a complex network of interactions with multiple cellu-
lar proteins acting either as co-activators or co-repressors.
Among these, MYC has been shown to be an important
down-regulator of CDKN2B expression via direct interac-
tionwithMIZ-1. Since the EBNA3proteins have previously
been shown to inhibitMYC transcription (61) and, at least
EBNA3C, reported to directly interact with MYC (74), we
investigatedwhether EBNA3A-induced down-regulation of
CDKN2B expression could be due to an indirect effect via
MYC. To examine this eventuality, we quantified the level
of expression of CDKN2B in LCLs treated or not with a
specific inhibitor of MYC: (Z,E)-5-(4-Ethylbenzylidine)-2-
thioxothiazolidin-4–1 or 10058-F4 (75). As shown in Fig-
ure 9B and as expected, following treatment with 10058-F4
of both LCLs, infected with EBVwt or EBV3A respectively,
the level of CDKN2B mRNA is increased (between 2.4
to 3×). Interestingly, the difference in the CDKN2B tran-
script levels between normal LCL and LCL infected with
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Figure 4. EBNA3A relocalizes MIZ-1 into the nucleus. Expression plasmids for Flag-MIZ-1 alone (A) or Flag-MIZ-1 together with Myc-EBNA3A were
transfected into HeLa cells (B and C). Proteins were visualized by indirect immunofluorescence using an anti-Flag polyclonal Ab (for detection of MIZ-1)
(panels b) and an anti-tag Myc polyclonal Ab (for detection of EBNA3A) (panels c). A Fluorolink Cy3-labeled goat anti-mouse IgG (H + L) antibody
and an Alexa Fluor 488 goat anti-rabbit antibody were used as secondary antibodies respectively. Cell nuclei were stained with Hoechst 33258 (Sigma)
(panels a). (C) Quantification of the number of cells in which MIZ-1 is strictly nuclear versus cytoplasmic/nucleo-cytoplasmic in cells transfected with
an expression vector for MIZ-1 or in cells co-transfected with expression vectors for MIZ-1 and EBNA3A. In the latter case, only cells co-expressing
EBNA3A together with MIZ-1 are taken into consideration. The results are the combination of two different experiments in which 1333 cells altogether
were observed.
EBV3A remains very similar, whether the cells are treated
or not with 10058-F4. This indicates that down-regulation
of CDKN2B expression by MYC or EBNA3A is mediated
by independent mechanisms.
EBNA3A inhibits MIZ-1 interaction with its co-activator
Nucleophosmin (NPM)
Finally, several cellular co-activators of MIZ-1 have been
previously identified, like NPM/B23 (38) which interacts
with the POZ domain of MIZ-1. Since EBNA3A also
interacts with MIZ-1’s POZ domain, we asked whether
EBNA3A could interfere withMIZ-1/NPM interaction. To
explore this hypothesis, we co-immunoprecipitated MIZ-
1/NPM complexes from LCLs infected either with EBVwt
or with EBV3A. As shown in Figure 9C, MIZ-1 was
expressed and immunoprecipitated in similar amounts
from both LCLs. Interestingly, NPM was efficiently
co-immunoprecipitated from the EBV3A-infected LCL,
whereas very little NPM was found associated with MIZ-1
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Figure 5. CDKN2B expression in lymphoblastoid cell lines is highly de-
pendent on the presence or absence of EBNA3A. Analysis of CDKN2B
mRNA expression levels from a normal LCL (wt) or an LCL established
from the same donor but infected with an EBNA3A-deficient recombi-
nant virus (D2 E3AmtB3) (LCL3A) by either standard RT-PCR using
actin mRNA as an internal control (A) or by real time RT-PCR (B). His-
togram bars represent values relative to housekeeping geneGAPDH. Error
bars represent standard deviation from four independent experiments. (C)
E3A-LCLdoxE3A cells were induced for EBNA3A expression by treat-
ment with 200 ng/ml Dox for 24, 48 or 72 h or left untreated. The per-
centage of cells expressing the NGFR––a control gene expressed simulta-
neously with EBNA3A from a common bicistronic promoter––upon Dox
treatment was evaluated by FACS to be 65% after 72 h. CDKN2B tran-
scripts in total RNA were quantified by RTqPCR normalized to GAPDH
RNA. EBNA3A protein levels were analyzed by western blotting (bottom
panel). The data shown are derived from a single experiment but are rep-
resentative of three experiments. Error bars represent standard deviation
from three qPCR replicates.
in the LCL infectedwith EBVwt although the overall level of
NPMwas identical in both cell lines. It should be noted that
NPM itself does not appear to interact with EBNA3A (Sup-
plementary Data Figure S4). These results strongly suggest
that EBNA3A inhibits MIZ-1-mediated transcriptional ac-
tivation by preventing the interaction of MIZ-1 with its
coactivator, NPM.
DISCUSSION
In this study we have developed a large-scale Y2H screen
to identify the main cellular partners of the EBNA3
proteins. We first identified the majority of the previ-
ously well-characterized cellular partners of the EBNA3s,
which validated the efficiency of our screen. In addition
Figure 6. EBNA3A down-regulates CDKN2B’s transcript expression lev-
els in cells treated with cisplatin. LCLwt and LCL3A were treated with 33
Mcisplatin or an equivalent amount of carrier (DMF). Cell aliquots were
collected at 0, 2, 4, 6, 8 and 12 h for RNA analysis and at 0, 8, 12 and 24 h
for cell cycle analysis. (A) CDKN2B transcripts in total RNAwere quanti-
fied byRTqPCRnormalized toGAPDHRNA. (B) Cells were stainedwith
propidium iodide and analysed by FACS. The data shown are derived from
a single experiment but are representative of three experiments. Error bars
represent standard deviation from three qPCR replicates.
to these already reported interactors, we have identified
22 new cellular partners for the EBNA3s. Most impor-
tantly, among the newly identified partners of the EBNA3s,
several––MCRS1,MEOX1,MED25, NF-YC and ZBTB17
(MIZ-1)––are known to play direct roles in transcriptional
regulation. MCRS1 is a putative regulatory component of
the chromatin remodeling INO80 complex, which is in-
volved in transcriptional regulation, DNA replication and
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Figure 7. EBNA3A activates the CDKN2Bminimal promoter and specif-
ically binds the INR in association with MIZ-1. (A) Schematic represen-
tation of the CDKN2Bp Luciferase reporter construct. The Firefly lu-
ciferase reporter gene was placed under the control of a −113/+160 bp
fragment from the human CDKN2B promoter. INR: Initiator element.
The arrow indicates the start of the transcription. (B) EBNA3A activates
theCDKN2Bminimal promoter. TheCDKN2Bp-Luc construct was trans-
fected into HeLa cells, together with a CMV-renilla LUC plasmid as inter-
nal control and expression plasmids for EBNA3A or EBNA3A 141–238
and MIZ-1 as indicated in the figure. Results are plotted relative to the
co-transfected CMV-renilla-LUC plasmid. Error bars represent standard
deviations from three replicate assays. Protein expression levels were con-
troled by western blotting using an anti-EBNA3A or an anti-MIZ-1 an-
tibody for one representative experiment (bottom panel). (C) EBNA3A
in association with MIZ-1 binds an oligonucleotide carrying the INR
sequence. Whole LCLwt extracts were subjected to precipitation, using
the CDKN2B promoter oligonucleotide––or a mutated control oligonu-
cleotide that does not bind MIZ-1––and examined for the indicated pro-
teins.
DNA repair (76). MEOX1 has recently been found to acti-
vate transcription of CDKN2A (encoding p16INK4A) in en-
dothelial cells in a DNA-binding-dependent manner (77).
Interestingly, CDKN2A is an important target of both
EBNA3A and EBNA3C in LCLs (7,6,17,16). It is thus
tempting to postulate that transcriptional repression of
CDKN2A expression by the EBNA3s involves an interac-
Figure 8. Epigenetic regulation of the CDKN2B locus by EBNA3A. (A)
Schematic representation of the CDKN2B promoter region depicting the
location of the fragments amplified in the ChIP-qPCR assays. The dark
gray box represents the initiator element, the light gray boxes, the first
two CDKN2B (p15INK4b) exons. (B and C) Comparative ChIP-qPCR
analysis between LCLs transformed with either wt EBV or EBNA3A
EBV, quantifying the H3K27me3 (B) or the H3K4me2 (C) across the
CDKN2B locus. The level of immunoprecipitated chromatin is expressed
as a percentage of the input chromatin. Primers that amplify the promoter
of inactive myoglobin (myo) were used as a control. Experiments were per-
formed twice with two independent chromatin preparations.
tion withMEOX1.MED25 is a component of theMediator
complex, a large polypeptide complex consisting of about
thirty polypeptides involved in the transcriptional regula-
tion of nearly all RNApolymerase II (RNAP II)-dependent
genes. Mediator forms a bridge between gene-specific tran-
scription factors and the RNAP II machinery via direct in-
teractions between specific mediator subunits and specific
transcription factors. MED25 in particular has been found
to interact with HSF, HNF4, SOX9 cellular factors and
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Figure 9. Mechanims of inhibition by EBNA3A of the MIZ-1-dependent
activation of the CDKN2B transcription. (A) EBNA3A-dependent down-
regulation ofCDKN2B expression is independent of CtBP. The CDKN2p-
Luc construct was transfected intoHeLa cells, togetherwith aCMV-renilla
LUC plasmid as internal control and expression plasmids for EBNA3A
or EBNA3A-CtBPmut and MIZ-1 as indicated in the Figure. Results are
plotted relative to the co-transfected CMV-renilla-LUC plasmid. Error
bars represent standard deviations from three replicate assays. Protein ex-
pression levels were controled by western blotting using an anti-EBNA3A
or an anti-MIZ-1 antibody for one representative experiment (bottompan-
els). (B) EBNA3A-dependent downregulation of CDKN2B expression is
independent of MYC. The LCLwt and LCL3A were treated or not with
the 10058-F4 MYC inhibitor. Quantification of CDKN2B mRNA levels
was performed by real time RT-PCR. Histogram bars represent values rel-
ative to housekeeping gene GAPDH. Error bars represent standard de-
viation from three replicate assays based on two different cDNAs. (C)
EBNA3A inhibits MIZ-1 interaction with its coactivator Nucleophosmin.
MIZ-1 was immunoprecipitated from eithe the LCLwt or the LCL3A with
an anti-MIZ-1 specific polyclonal antibody or with an unrelated antibody.
Immunoprecipitated MIZ-1 and co-immunoprecipitated Nucleophosmin
(NPM) proteins were analyzed by western blotting. Inputs correspond to
5% of the cell extract used for immunoprecipitation.
VP16 from herpes simplex virus (for a review see (78)). In-
teraction between the EBNA3s and the mediator complex
via MED25 is thus of particular interest and needs to be
further explored. NF-YC is one of the subunits of Nuclear
transcription factor Y (NF-Y), a ubiquitous heteromeric
transcription factor composed of three subunits - NF-YA,
NF-YB and NF-YC - that binds CCAAT elements in the
core promoter of many genes (for a review see (79)). In-
terestingly, it has been shown that EBNA3C and EBNA3A
cooperate to repress expression of the proapoptotic tumor-
suppressor BCL2L11 (BIM) in BL cell lines (15) and that
EBNA3C can be recruited to the BIM promoter proxi-
mal to the transcription start site (TSS) (80). Moreover, it
has recently been shown, in rat sympathetic neurons, that
the BCL2L11 core promoter is regulated by NF-Y via a
CCAAT box proximal to the TSS (81). Since the CCAAT
box found in the rat BCL2L11 promoter is conserved in the
human gene promoter, it is tempting to hypothesize that the
EBNA3s are specifically recruited onto the BCL2L11 pro-
moter by interacting with NF-Y bound to the CCAAT box.
Work is currently under progress in our laboratory to de-
termine whether this is indeed the case. Finally, MIZ-1 is a
transcriptional regulator involved in the expression ofmany
genes involved in cell control (CDKN1A, CDKN2B and
CDKN1C for example) or apoptosis regulation (BCL2). By
interacting with such crucial factors, the EBNA3 proteins
are likely to induce a complete reprogrammation of tran-
scription in B cells following infection by EBV.
Given the important role of MIZ-1 in the control of cell
proliferation, we decided to focus our attention on the func-
tional role of this particular interaction in EBV-driven B-
cell proliferation. Following our original finding that MIZ-
1 interacts with the three EBNA3 proteins, we subsequently
studied more specifically the interaction between MIZ-1
and EBNA3A. EBNA3A interacts both with the NT POZ
domain of MIZ-1 and with a CT domain located between
aa 740–803. The main interaction domain in EBNA3A
is localized within the NT and corresponds to a ‘homol-
ogy domain’––from aa 90–310 for EBNA3A––common to
all three EBNA3s. However, the precise interacting sub-
regions involved in contacting respectively the POZ domain
of MIZ-1 and its CT region are likely to be different since
although interaction with the CT of MIZ-1 is completely
lost in deletion mutant, EBNA3A 1–172, this mutant still
interacts with the POZ domain. Thus, interaction between
the two proteins appears to be particularly complex andwill
require structural studies in order to be characterized fur-
ther.
One of the best characterized target genes of MIZ-1
is the cyclin-dependent kinase inhibitor (CDKI) p15INK4B
(CDKN2B) (37,40). Comparison of the CDKN2B tran-
script levels clearly shows that EBNA3A presence corre-
lates with a lower level of CDKN2B. However, although
we obtained similar results with different combinations
of LCLs––established from different donors and infected
with either wild-type or one of two different types of
EBNA3A-mutated viruses––we were concerned by the fact
that CDKN2B had not been reported to be an EBNA3A-
regulated gene in previous microarray studies (7). In order
to clarify the question, we used conditions in which the ex-
pression level of the gene was induced by treatment of the
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cells with theDNA-damaging agent cisplatin, and were able
to confirm our original observation of a significant down-
regulation of the CDKN2B transcript level in the presence
of EBNA3A. Thus by keeping a low level ofCDKN2B tran-
scripts, EBNA3A probably participates in delaying cell cy-
cle arrest following DNA damage.
By using a luciferase reporter assay in which MIZ-1
activates expression of the luciferase gene placed under
the control of a minimal CDKN2B promoter containing
mainly the Inr known to directly bindMIZ-1, we found that
EBNA3A––but not a mutant of EBNA3A altered for its ca-
pacity to interact withMIZ-1––was able to antagonizeMiz-
dependent activation of the CDKN2B promoter. This sug-
gests that interaction with MIZ-1 is indeed directly respon-
sible for the downregulation of the CDKN2B transcript
level observed in the LCLs.Moreover, by using an oligo-pull
down assay, we found that EBNA3A specifically associates
with MIZ-1 bound on its specific Inr recognition sequence,
strongly suggesting that MIZ-1 recruits EBNA3A to the
DNA. Similar results were obtained for EBNA3C in these
two assays (data not shown). In the event, however, we were
not able to obtain convincing ChIPs of the CDKN2B pro-
moter region––neitherwith an anti-EBNA3Anorwith anti-
EBNA3C antibodies––whereas we efficiently immunopre-
cipitated the ADAM28/ADAMDEC1 intergenic region,
previously described as a target for both EBNA3A and
EBNA3C (29,33). However, in a recent paper, Skalska et
al. (17), using a LCL established with a recombinant EBV
expressing an EBNA3C protein tagged with a Flag epi-
tope at its CT, and an anti-Flag antibody, succeeded in per-
forming ChIP experiments that demonstrate the presence
of EBNA3C immediately proximal to all three CDKN2B,
ARF and INK4a (these latter two being jointly referred to
asCDKN2A) transcription starts. This latter result strongly
supports the idea that the EBNA3s are indeed recruited by
MIZ-1 to theCDKN2B promoter proximal region. That we
could not detect this promoter region in our ChIP assays us-
ing antibodies against both EBNA3A and EBNA3C, sug-
gests that the epitopes recognised by these antibodies are
not likely to be accessible in the context of the CDKN2B
promoter.
Finally, we were interested in investigating the mecha-
nisms involved in the repression of MIZ-1 transcriptional
activation. Since the EBNA3s have previously been shown
to be involved in inducing epigenetic modifications at vari-
ous promoters (27,16,31), we investigated the impact of the
absence of EBNA3A on the methylation state of the chro-
matin at theCDKN2B locus and accordingly observed a de-
crease in the amount of H3K27me3 but no major change
in the amount of H3K4me2. This suggests that, similar
to what has been described for the BCL2L11 (27) pro-
moter, EBV downregulates CDKN2B expression likely by
triggering recruitment of the polycomb repressive complex
2 (PRC2) leading to trimethylation of histone H3 lysine
27 at the CDKN2B locus. Furthermore, in accordance to
what was previously observed in the case of the BCL2L11
promoter, absence of only EBNA3A protein is sufficient
to completely inhibit H3K27 methylation at the CDKN2B
promoter. Whether EBNA3C cooperates with EBNA3A
for triggering epigenetic modifications at the CDKN2B
promoter––in a similar way to what has been found in
the case of the BCL2L11 promoter––remains to be inves-
tigated.
Besides this role of the EBNA3s in triggering epigenetic
modification, another way in which EBNA3A could inhibit
MIZ-1-dependent transcriptional activationwould be to in-
terfere with MIZ-1 binding to its coactivator(s). Here we
demonstrate that EBNA3A inhibitsMIZ-1 interaction with
its coactivator, NPM. This result is in accordance with our
mapping of the EBNA3A interaction domain to the POZ
domain of MIZ-1 which happens also to be the interac-
tion domain with NPM (38). Taken together, these results
suggest two levels of repression of MIZ-1’s target promoter
CDKN2B by EBNA3A : first, EBNA3A binding to MIZ-
1 displaces MIZ-1 coactivator NPM, thus inhibiting MIZ-
1-dependent transcriptional activation. That this event oc-
curs promptly following the expression of EBNA3A, was
revealed in the experiments where EBNA3A expression was
induced by Dox. Second, EBNA3A––possibly in coopera-
tion with EBNA3C––triggers the recruitment of PRC2 as
has been previously described for the BCL2L11 promoter.
Interestingly, another link betweenEBV andNPMhas been
recently documented in a paper by Liu et al. (82). Indeed,
the authors show that NPM expression is induced in EBV-
infected cells and they demonstrate an essential role for
NPM in chaperoning EBNA2 recruitment to the latency-
associated membrane protein 1 (LMP1) promoter. Thus
NPM appears to be essential for the activation of the EBV
genes expressed during latency and consequently for EBV-
driven B-cell proliferation. Paradoxically, by acting as a
coactivator of MIZ-1, NPM also has the capacity to en-
hance expression of the cell cycle inhibitors CDKN2B and
CDKN1A (38). By inhibiting the interaction between NPM
andMIZ-1, the EBNA3s could thus play an important role
by counteracting the inhibiting effect of NPM on cell pro-
liferation.
Although the EBNA3 proteins were for long recog-
nized for their capacity as transcriptional regulators, un-
til recently only RBP-J was consistently reported to be a
DNA-binding protein that directs the EBNA3s to specific
promoter elements. On the other hand, ChIP-sequencing
(ChIP-seq) analyses identified up to 13 000 genomic sites
for the EBNA3s (32,33), of which only a few (around 16%)
coincide with RBP-J binding sites. Moreover, a majority
of EBNA3 binding sites are localized in enhancer regions
and it has been suggested that EBNA3 proteins regulate
transcription by modulating enhancer-promoter loop for-
mation (33). However, although ChIP-seq analysis revealed
frequent co-occupancy with a handful of cellular transcrip-
tion factors, the cellular proteins allowing the formation of
such loop have not as yet been defined (32,33). Here we de-
scribe, for the first time, the interaction of the EBNA3s with
MIZ-1, a transcription factor that binds Inrs present in the
core promoters of genes. This factor is thus a very good
candidate to participate––as a promoter binding factor––in
the enhancer-promoter loop formation promoted by the
EBNA3s.
Finally, our findings are in line with the idea of a cen-
tral role for MIZ-targeting in tumorigenesis. It was recently
proposed that the functional interaction betweenMYC and
MIZ-1 mediates resistance to anti-mitogenic signals and
that in the context of MYC deregulation this interaction
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could play a central role in tumorigenesis (83). That MIZ-1
potentially plays an important role in the course of onco-
genesis is reinforced by the notion that MIZ-1 is targeted
by oncovirus proteins such as the EBV EBNA3s as dis-
cussed in this paper and also by the Human Papilloma
virus type 16 E7 oncoprotein (84). It is interesting to note
that among the different B cell lymphoma and lymphopro-
liferations associated with EBV, the EBNA3s are usually
not expressed in Burkitt’s lymphoma cells where a translo-
cation involving the MYC gene results in MYC overex-
pression, whereas the EBNA3s expression––at least that of
EBNA3A and EBNA3C––is central for efficient prolifera-
tion of EBV growth-transformed LCLs. It is thus tempt-
ing to postulate that MYC overpexression in Burkitt’s lym-
phoma and EBNA3s expression in EBV-associated lym-
phoproliferations fulfil––via MIZ-1––similar functions im-
portant for continuous cell proliferation.
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